
@ShahidNShah
What You Should Know:
– 23andMe, a human genetics and biotechnology company, has announced its decision to initiate voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the Eastern District of Missouri.
– The bankruptcy filing is aimed at facilitating a structured sale process to maximize the value of its business. The company has assured its customers that operations will continue as normal and that there will be no changes to the way customer data is stored, managed, or protected.
Read on hitconsultant.net
In today’s healthcare environment, patient safety and staff protection are paramount. Hospitals are dynamic environments where multiple individuals—patients, healthcare providers, visitors, and …
Posted Mar 24, 2025 Artificial Intelligence Healthcare Innovation
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2025 Netspective Foundation, Inc. All Rights Reserved.
Built on Apr 1, 2025 at 12:54pm